Carbon nanoparticles downregulate expression of basic fibroblast growth factor in the heart during embryogenesis

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3427-3435

  Wierzbicki, Mateusz ^a   Sawosz, Ewa ^a   Grodzik, Marta ^a   Hotowy, Anna ^a   Prasek, Marta ^a   Jaworski, Sławomir ^a   Sawosz, Filip ^b   Chwalibog, André ^b  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

bFGF; Diamond; Graphite; Nanoparticles; Vasculogenesis; VEGF

Indexed keywords

BETA ACTIN; CARBON NANOPARTICLE; DIAMOND; ELONGATION FACTOR 1ALPHA; FIBROBLAST GROWTH FACTOR 2; GRAPHITE; NANOPARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACTB GENE; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BFGF GENE; BODY WEIGHT; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; EEF1A2 GENE; EMBRYO; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; HEART DEVELOPMENT; HEART WEIGHT; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SERUM; VASCULARIZATION; VEGF GENE;

BFGF; DIAMOND; GRAPHITE; NANOPARTICLES; VASCULOGENESIS; VEGF;

ANIMALS; CARBON; CHICK EMBRYO; DOWN-REGULATION; EMBRYONIC DEVELOPMENT; FETAL HEART; FIBROBLAST GROWTH FACTOR 2; NANOPARTICLES;

EID: 84884548825     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S49745     Document Type: Article

References (48)

1. Schrand AM, Ciftan SA, Shenderova OA. Nanodiamond particles: properties and perspectives for bioapplications. Crit Rev Solid State Mat Sci. 2009;34(1-2):18-74.
2. Huang H, Pierstorff E, Liu K, Osawa E, Ho D. Nanodiamond-mediated delivery of therapeutics via particle and thin film architectures. In: Ho D, editor. Nanodiamonds: Applications in Biology and Nanoscale Medicine: New York: Springer: Science+Business Media; 2010:151-174.
3. Schrand AM, Dai L, Schlager JJ, Hussain SM, Osawa E. Differential biocompatibility of carbon nanotubes and nanodiamonds. Diamond Relat Mater. 2007;16(12):2118-2123.
4. Liu KK, Chen MF, Chen PY, et al. Alpha-bungarotoxin binding to target cell in a developing visual system by carboxylated nanodiamond. Nanotechnology. 2008;19(20):205102.
5. Thomas V, Halloran BA, Ambalavanan N, Catledge SA, Vohra YK. In vitro studies on the effect of particle size on macrophage responses to nanodiamond wear debris. Acta Biomater. 2012;8(5):1939-1947.
6. Puzyr AP, Baron AV, Purtov KV, et al. Nanodiamonds with novel properties: a biological study. Diamond Relat Mater. 2007;16(12): 2124-2128.
7. Bakowicz-Mitura K, Bartosz G, Mitura S. Influence of diamond powder particles on human gene expression. Surf Coat Techn. 2007;201(13): 6131-6135.
8. Niemiec T, Szmidt M, Sawosz E, Grodzik M, Mitura K. The effect of diamond nanoparticles on redox and immune parameters in rats. J Nanosci Nanotechnol. 2011;11(10):9072-9077.
9. Karpukhin AV, Avkhacheva NV, Yakovlev RY, et al. Effect of detonation nanodiamonds on phagocyte activity. Cell Biol Int. 2011;35(7):727-733.
10. Grodzik M, Sawosz E, Wierzbicki M, et al. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo. Int J Nanomedicine. 2011;6:3041-3048.
11. Murugesan S, Mousa SA, O'connor LJ, Lincoln DW, Linhardt RJ. Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Lett. 2007;581(6):1157-1160.
12. Fioritoa S, Serafinob A, Andreolab F, Bernierc P. Effects of fullerenes and single-wall carbon nanotubes on murine and human macrophages. Carbon. 2006;44(6):1100-1105.
13. Eriksson C, Nygren H. The initial reactions of graphite and gold with blood. J Biomed Mater Res. 1997;37(1):130-136.
14. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22(4):201-207.
15. Tomanek RJ, Lotun K, Clark EB, Suvarna PR, Hu N. VEGF and bFGF stimulate myocardial vascularization in embryonic chick. Am J Physiol. 1998;274(5 Pt 2):H1620-H1626.
16. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc. 2000;5(1):40-46.
17. Bikfalvi A, Klein S, Pintucci G, Rifkin D. Biological roles of fibroblast growth factor-2. Endocrine Rev. 1997;18(1):26-45.
18. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol. 2000;32(2):115-120.
19. Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2003;3(2):95-117.
20. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005;438(7070):937-945.
21. Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007;16 Spec No 2:R140-R149.
22. Knudsen TB, Kleinstreuer NC. Disruption of embryonic vascular development in predictive toxicology. Birth Defects Res C Embryo Today. 2011;93(4):312-323.
23. Kleinstreuer NC, Judson RS, Reif DM, et al. Environmental impact on vascular development predicted by high-throughput screening. Environ Health Perspect. 2011;119(11):1596-1603.
24. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol. 1996;40(6):1189-1197.
25. Wierzbicki M, Sawosz E, Grodzik M, Prasek M, Jaworski S, Chwalibog A. Comparison of anti-angiogenic properties of pristine carbon nanoparticles. Nanoscale Res Lett. 2013;8(1):195.
26. SAS Institute Inc. Base SAS 9.2 Procedures Guide. Cary, NC: SAS Institute Inc: 2009.
27. Ribatti D. Chorioallantoic membrane in the study of angiogenesis, antiangiogenesis, and the vascularization of grafted tissues. In: Ribatti D. The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis. NewYork: Springer: Science+Business Media; 2010L:17-40.
28. Brooks PC, Montgomery AM, Cheresh DA. Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol. 1999;129:257-269.
29. Gvozdjan DM, Bowden ET, Wellstein A. A novel chicken embryo model for the investigation of drugs with antimetastatic properties. Clin Pharmacol Ther. 2004;75(2):P60.
30. Rashidi H, Sottile V. The chick embryo: hatching a model for contemporary biomedical research. Bioessays. 2009;31(4):459-465.
31. Griffitt RJ, Weil R, Hyndman KA, et al. Exposure to copper nanoparticles causes gill injury and acute lethality in zebrafish (Danio rerio). Environ Sci Technol. 2007;41(23):8178-8186.
32. Wang B, Feng WY, Wang TC, et al. Acute toxicity of nano- and microscale zinc powder in healthy adult mice. Toxicol Lett. 2006;161(2): 115-123.
33. Terentyuk GS, Maslyakova GN, Suleymanova LV, et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics. 2009;2(5): 292-302.
34. Marcon L, Riquet F, Vicogne D, Szunerits S, Bodartb JF, Boukherroub R. Cellular and in vivo toxicity of functionalized nanodiamond in Xenopus embryos. J Mater Chem. 2010;20:8064-8069.
35. Cheng J, Gu YJ, Wang Y, Cheng SH, Wong WT. Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos. Int J Nanomedicine. 2011;6: 2007-2021.
36. Yuan Y, Wang X, Jia G, et al. Pulmonary toxicity and translocation of nanodiamonds in mice. Diamond Relat Mater. 2010;19(4):291-299.
37. Abraham JA, Mergia A, Whang JL, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein basic fibroblast growth factor. Science. 1986;233(4763):545-548.
38. Ribatti D, Presta M. The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. J Cell Mol Med. 2002;6(3):439-446.
39. Meng H, Xing G, Sun B, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano. 2010;4(5): 2773-2783.
40. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev. 1994;8(24):3032-3044.
41. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89(6):981-990.
42. Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res. 2002;11(1):19-32.
43. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
44. Ladoux A, Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun. 1993;195(2):1005-1010.
45. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn. 1995;203(1):80-92.
46. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
47. Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15(5):482-489.
48. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273-286.